Advances in Clinical and Experimental Medicine
2018, vol. 27, nr 10, October, p. 1391–1395
Publication type: original article
The importance of serum interleukin-20 levels in patients with Behçet’s disease
1 Department of Rheumatology, Ankara Numune Training and Research Hospital, Turkey
2 Department of Internal Medicine, Mersin State Hospital, Turkey
3 Department of Clinical Biochemistry, Ankara Numune Training and Research Hospital, Turkey
4 Department of Immunology and Allergy, Medical Faculty, Ankara University, Turkey
5 Department of Internal Medicine, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
Background. Behçet’s disease (BD) is a complex multisystemic disease with an unknown origin, which presents with aphthous and genital ulcers, cutaneous lesions, arthritis, ocular lesions, and defects in the gastrointestinal and central nervous systems.
Objectives. In this study, we examined the relationship between serum interleukin-20 (IL-20) levels and disease activity in BD patients.
Material and Methods. A total of 45 BD patients diagnosed according to the BD diagnosis criteria determined by the International Study Group for Behçet’s Disease were included in the study. Out of 45 patients, 17 had inactive BD and 28 had active BD. The control group consisted of 25 healthy subjects. The IL-20 levels of all the groups were detected and compared with each other. Serum IL-20, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels were examined.
Results. The IL-20 levels of the active BD patient group were significantly higher than in the control group (p < 0.001) and in the inactive BD patient group (p < 0.001). No statistically significant difference was detected between the IL-20 levels of the control group and the inactive BD patient group (p = 0.2).
Conclusion. Higher IL-20 levels in active BD patients, when compared to inactive BD patients and healthy controls indicate that the disease is an inflammatory one and IL-20 plays a role in the disease pathogenesis. Moreover, it can be concluded that IL-20 might have a role in the complex process of the settlement and activation of the disease.
cytokines, inflammation, Behçet’s disease, interleukin-20
- Mat MC, Sevim A, Fresko I, Tüzün Y. Behçet’s disease as a systemic disease. Clin Dermatol. 2014;32:435–442.
- Yurdakul S, Hamuryudan V, Yazıcı H. Behçet syndrome. Curr Opin Rheumatol. 2004;16:38–42.
- Banfioli AA, Orefice F. Behçets disease. Semin Ophthalmol. 2005;20(3):199–206.
- Akdeniz N, Esrefoglu M, Keleş MS, Karakuzu A, Atasoy M. Serum interleukin-2, interleukin-6, tumour necrosis factor-alpha and nitric oxide levels in patients with Behcet’s disease. Ann Acad Med Singapore. 2004;33:596–599.
- Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K. Cytokine profile in Behçet’s disease patients. Relationship with disease activity. Scand J Rheumatol. 2002;31:205–210.
- Adam B, Calikoglu E. Serum interleukin-6, procalcitonin and C reactive protein levels in subjects with active Behçet’s disease. J Eur Acad Dermatol Venereol. 2004;18:318–320.
- Aridogan BC, Yildirim M, Baysal V, Inaloz HS, Baz K, Kaya S. Serum levels of IL-4, IL-10, IL-12, IL-13 and IFN-gamma in Behçet’s disease. J Dermatol. 2003;30:602–607.
- Volk H, Asadullah K, Gallagher G, Sabat R, Grutz G. IL-10 and its homologs: Important immune mediators and emerging immunotherapeutic targets. Trend Immunol. 2001;22(8):414–417.
- Blumberg H, Conklin D, Xu WF, et al. Interleukin 20: Discovery, receptor identification, and role in the epidermal function. Cell. 2001;104(1):9–19.
- Dumoutier L, Leemans C, Lejeune D, Kotenko SV, Renauld JC. Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. J Immunol. 2001;167(7):3545–3549.
- Kragstrup TW, Otjaker K, Holm C, et al. The expression of IL-20 and IL-24 and their shared receptors are increased in rheumatoid arthritis and spondyloarthropathy. Cytokine. 2008;41:16–23.
- Wei CC, Chen WY, Wang YC, et al. Detection of IL-20 and its receptors on psoriatic skin. Clin Immunol. 2005;117(1):65–72.
- Hsieh MY, Chen WY, Jiang MJ, et al. IL-20 promotes angiogenesis in a direct and indirect manner. Genes Immun. 2006;7(3):234–242.
- Panutsopulos D, Papalambros E, Sigala F, Zafiropoulos A, Arvantis DL, Spandidos DA. Protein and mRNA expression levels of VEGF-A and TGF-beta1 in different types of human coronary atherosclerotic lesions. Int J Mol Med. 2005;15(4):603–610.
- Bodur H, Borman P, Ozdemir Y, Atan C, Kural G. Quality of life and life satisfaction in patients with Behçet’s disease: Relationship with disease activity. Clin Rheumatol. 2006;25:329–333.
- Lawton G, Chamberlain MA, Bhakta BB, Tennant A. Adv Exp Med Biol. 2003;528:149–151.
- Kunz S, Wolk K, Whitte, et al. Interleukin-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp Dermatol. 2006;15(12):991–1004.
- Li HH, Lin YC, Chen PJ, et al. Interleukin-19 upregulates keratinocyte growth factor and is associated with psoriasis. Br J Dermatol. 2005;153(3):591–595.
- Otkjaer K, Kragballe K, Funding AT, et al. The dynamics of gene expreesion of IL-19 and IL-20 and their receptors in psoriasis. Br J Dermatol. 2005;153(5):911–918.
- Romer J, Hasselager E, Norby PL, et al. Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short term treatment with cyclosporine a or calcipotriol. J Invest Dermatol. 2003;121(6):1306–1311.
- Smeets TJM, Chandrasekher Y, Haringman JJ, Tak PP. IL-20 is expressed in inflamed synovium of patients with psoriatic arthritis and rheumatoid arthritis. Arthritis Res Therapy. 2004;6:6–9.
- Li Z, Liu B, Arvydase M, et al. Gene expression profiling in autoimmune non-infectious uveitis disease. J Immunol. 2008;181(7):5147–5157.